12/30/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Diclofenac sodium

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Diklofenak – lokalt

Diklofenak – lokalt

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000 Sep;60(3):555-74

  2. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824-9.

  3. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology. 1997;56:282-92.

  4. Souter D, Harding J, McCowan L, O´Donnell C, McLeay E, Baxendale H. Antenatal indomethacin - adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998;38:11-6.

  5. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353.

  6. Hernández-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110 Suppl 3A:20S-7S.

  7. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.

  8. Torloni MR, Cordioli E, Zamith MM, Hisaba WJ, Nardozza LM, Santana RM et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound Obstet Gynecol. 2006;27(2):227-9.

  9. Le Duc K, Gilliot S, Baudelet JB, Mur S, Boukhris MR, Domanski O et al. Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy. Front Pharmacol. 2021;12:756056.

  10. Benguigui L, Atallah A, Joly H, Cottin J, Claris O, Butin M. Prenatal constriction of ductus arteriosus following inadvertent maternal exposure to topical non-steroidal anti-inflammatory drug. Ultrasound Obstet Gynecol. 2021;58(5):780-781.

  11. Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97:312-6.

  12. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.

  13. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-70.

  14. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79.

  15. Ericson A, Kallen BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5.

  16. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-61.

  17. Ferencz C, C.-V.A., Loffredo CA, Wilson PD, Genetics and environmental risk factors of major cardiovascular malformations: the Baltimore-Washington Infant Study: 1981–1989. Perspect Ped Cardiol 5. Vol. 5. 1997, New York: Futura Publishing Comp., Inc.

  1. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000 Sep;60(3):555-74
  2. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40:824-9.
  3. Norton ME. Teratogen update: fetal effects of indomethacin administration during pregnancy. Teratology. 1997;56:282-92.
  4. Souter D, Harding J, McCowan L, O´Donnell C, McLeay E, Baxendale H. Antenatal indomethacin - adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998;38:11-6.
  5. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353.
  6. Hernández-Díaz S, García-Rodríguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110 Suppl 3A:20S-7S.
  7. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.
  8. Torloni MR, Cordioli E, Zamith MM, Hisaba WJ, Nardozza LM, Santana RM et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound Obstet Gynecol. 2006;27(2):227-9.
  9. Le Duc K, Gilliot S, Baudelet JB, Mur S, Boukhris MR, Domanski O et al. Case Report: Persistent Pulmonary Hypertension of the Newborn and Narrowing of the Ductus Arteriosus After Topical Use of Non-Steroidal Anti-Inflammatory During Pregnancy. Front Pharmacol. 2021;12:756056.
  10. Benguigui L, Atallah A, Joly H, Cottin J, Claris O, Butin M. Prenatal constriction of ductus arteriosus following inadvertent maternal exposure to topical non-steroidal anti-inflammatory drug. Ultrasound Obstet Gynecol. 2021;58(5):780-781.
  11. Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97:312-6.
  12. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.
  13. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001;322:266-70.
  14. Ofori B, Oraichi D, Blais L, Rey E, Berard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-79.
  15. Ericson A, Kallen BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-5.
  16. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-61.
  17. Ferencz C, C.-V.A., Loffredo CA, Wilson PD, Genetics and environmental risk factors of major cardiovascular malformations: the Baltimore-Washington Infant Study: 1981–1989. Perspect Ped Cardiol 5. Vol. 5. 1997, New York: Futura Publishing Comp., Inc.